Y-mAbs Therapeutics, Inc.

NasdaqGS YMAB

Y-mAbs Therapeutics, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -33.66%

Y-mAbs Therapeutics, Inc. EBIT Margin is -33.66% for the Trailing 12 Months (TTM) ending September 30, 2024, a -31.36% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

Y-mAbs Therapeutics, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was -25.63%, a 91.41% change year over year.
Y-mAbs Therapeutics, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -298.50%, a -37.77% change year over year.
Y-mAbs Therapeutics, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -216.66%.

Key data

Date	EBIT Margin	EPS (Basic)	EPS (Diluted)	Shares (Basic, Weighted)

NasdaqGS: YMAB

Y-mAbs Therapeutics, Inc.

CEO	Mr. Michael Rossi
IPO Date	Sept. 21, 2018
Location	United States
Headquarters	230 Park Avenue
Employees	100
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Pharmaceuticals Vaccines

Description

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

Key trends

Past 5 years